Trulieve became the first U.S. cannabis operator listed on the NYSE.
Green Thumb Industries could be an exchange listing candidate.
Strong cash flow and liquidity support Green Thumb's financial position.
Trulieve Cannabis (NYSE:TRLV) became the first U.S. cannabis operator to list on the New York Stock Exchange on June 10 after a major change in federal marijuana policy. With that, the company accomplished something U.S. cannabis operators had been trying to do for years. And now, attention is turning to which company could follow.
One potential candidate is Green Thumb Industries (OTC:GTBIF), one of the country's largest cannabis operators. It definitely has the revenue, cash flow, and financial resources to make a compelling case for a major U.S. exchange listing. Still, regulatory obstacles remain, and the company hasn't announced an approved uplisting.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Trulieve's NYSE debut followed the federal government's April 2026 decision to move state-licensed medical marijuana into Schedule III, allowing sales of drugs with potential therapuetic value as opposed to Schedule I, which bars sales of dangerous substances. That change created an opportunity for medical cannabis companies to access major U.S. exchanges.
However, Trulieve also had to restructure its business, separating its medical operations from businesses serving both recreational and medical customers. Recreational marijuana remains federally prohibited, which creates complications for other multi-state operators.
Green Thumb's latest financial results provide a strong argument for its consideration. In Q3, the company reported revenue of $324.4 million, representing an increase of 11% from the previous year. Normalized earnings before interest, taxes, depreciation, and amortization (EBITDA) reached $89.4 million, representing a margin of 27.6%, and the company generated $58.3 million in operating cash flow during the quarter.
Its balance sheet is another advantage. Green Thumb ended September with $316 million in cash and $277.3 million in total debt, including $177 million in senior debt. Management has also been returning capital to shareholders. Since launching its first stock repurchase program in 2023, the company has bought back about 29.5 million shares for $203.4 million.
Green Thumb still faces significant obstacles. Unlike Trulieve's newly structured medical business, Green Thumb operates in both medical and recreational cannabis markets. That creates regulatory complications that could prevent an NYSE or Nasdaq listing without additional federal reform or corporate restructuring.
Image source: Getty Images.
Its financial performance isn't flawless either. Despite increasing revenue, Green Thumb's net loss was $4.8 million, or $0.02 per share, based on generally accepted accounting principles (GAAP) Still, an eventual listing could provide access to a broader investor base, improve trading liquidity, and potentially attract institutional investors currently unable or unwilling to purchase over-the-counter cannabis stocks.
To clarify, Green Thumb hasn't announced a confirmed timetable for such a move. But if federal cannabis reform continues and major exchanges become more accessible to U.S. operators, Green Thumb's financial strength makes it a credible candidate to follow Trulieve onto Wall Street.
Before you buy stock in Green Thumb Industries, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Green Thumb Industries wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $322,605!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $927,581!*
Now, it’s worth noting Stock Advisor’s total average return is 790% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 20, 2026.
Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool recommends Green Thumb Industries and Nasdaq. The Motley Fool has a disclosure policy.